肽基精氨酸脫亞氨酶Ⅳ(PADI4)活性蛋白
Active Peptidyl Arginine Deiminase Type IV (PADI4)
PAD; PADI5; PDI4; PDI5; Peptidyl Arginine Deiminase Type V; Peptidylarginine deiminase IV
- 編號UAPF709Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點6.0
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 756 ¥ 1890 ¥ 3780 ¥ 11340 ¥ 28350
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
活性實驗
Peptidylarginine deiminase 4 (PADI4) is an enzyme that plays an important role in the organism. It mainly catalyzes the conversion of arginine residues in proteins into citrulline residues. PADI4 plays a key role in various physiological processes such as cell differentiation and immune response. The abnormal expression or change in its activity is closely related to autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, making it an important target in the research of these related diseases.The activity of recombinant human PADI4 is determined by its ability to catalyze Benzoyl-arginine ethyl ester (BAEE) to form citrulline.The reaction was performed in 50 mM Tris, 0.1 M NaCl, 10 mM CaCl2, 5 mM DTT solution (Assay Buffer, pH 7.5). A total volume of 300 μL was achieved by adding 75 μL of 100 μg/mL PADI4 to 75 μL of 10 mM BAEE. After 30-minute incubation at 37°C, the reaction mixture was acidified with color-developing solution containing ammonium iron sulfate and measured at 540 nm .
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPF709Hu01 | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPF709Hu01 | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAF709Hu01 | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)多克隆抗體 | IHC |
| UMAF709Hu21 | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)單克隆抗體 | WB |
| UMAF709Hu22 | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)單克隆抗體 | WB |
| UMAF709Hu23 | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)單克隆抗體 | WB |
| UMAF709Hu24 | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)單克隆抗體 | WB |
| UFAF709Hu02 | 抗肽基精氨酸脫亞氨酶Ⅳ(PADI4)單克隆抗體 | FCM |
| USEF709Hu | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMF709Hu | 肽基精氨酸脫亞氨酶Ⅳ(PADI4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Arthritis Res Ther. | Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility [Pubmed:Pmc4229860] |
| Journal of Molecular?Cell?Biology | Peptidylarginine deiminase 4 concentration, but not polymorphisms, is associated with ICU mortality in septic shock patients [Pubmed:30044533] |
| Journal of Inflammation Research | Release of active peptidylarginine deiminase into the circulation during acute inflammation induced by coronary artery bypass surgery [Pubmed: 31213874] |
| Revista da Associacao Medica Brasileira | Evaluation of peptidylarginine deiminase 4 and PADI4 polymorphisms in sepsis-induced acute kidney injury [] |
